Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia × Idarubicin × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 11 Myelodysplastic Syndromes 2 Leukemia, Biphenotypic, Acute 2 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1

Interventions

venetoclax 10 Cyclophosphamide 6 Azacitidine 5 fludarabine phosphate 4 fludarabine 4 Cytarabine 4 Mycophenolic Acid 3 Mesna 3 Melphalan 3 Bone Marrow Transplantation 3 ruxolitinib 2 revumenib 2 quizartinib 2 ponatinib 2 pembrolizumab 2 Whole-Body Irradiation 2 Rituximab 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Decitabine 2 Daunorubicin 2 Busulfan 2 pirtobrutinib 1 pegaspargase 1 obinutuzumab 1 nelarabine 1 ibrutinib 1 cedazuridine 1 capivasertib 1 blinatumomab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06578247 2026-02-27

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡